Technology ID
TAB-4509

High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis

E-Numbers
E-146-2019-0
Lead Inventor
Swenson, Rolf (NHLBI)
Co-Inventors
Koretsky, Alan (National Institute of Neurological Disorders and Stroke)
Pothayee, Nikorn (National Institute of Neurological Disorders and Stroke (NINDS))
Sail, Deepak (NHLBI)
Applications
Research Materials
Medical Devices
Diagnostics
Development Stages
Pre-clinical (in vivo)
Lead IC
NHLBI
ICs
NHLBI

This technology includes a peptide containing alternating Alanine and Lys(DOTA-Gd) residues can be used to increase the MRI relaxivity of a peptide. The low molecular weight construct can be appended to proteins, antibodies and peptides to increase MRI signals. This approach offers advantages over previous dendrimeric constructs. The increased MRI signal may allow effective neuronal tracing of peptides that when misfolded and transported from the gut to the brain may lead to inflammation and serious diseases including Alzheimer’s (A-beta), Parkinson’s Disease, Lewey Body Dementia, and Multiple Systems atrophy (alpha synuclein), Creutzfeld-Jakob disease, and Amyotrophic lateral sclerosis.

Commercial Applications
For use in diagnostic MRI applications.

Competitive Advantages
Multivalent chelated Gd can be efficiently constructed on a peptide scaffold, with substantial increase in relaxivity (i.e., higher MRI signal), with minimum molecular weight increase and can be efficiently added to proteins, antibodies, and proteins for targeted MRI applications in disease diagnosis.
Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov